Saccharomyces cerevisiae fungemia in a critically ill patient with acute cholangitis and long term probiotic use

Mustafa Fadhel; Swapnil Patel; Edward Liu; Michael Levitt; Arif Asif

doi:10.1016/j.mmcr.2018.11.003

Saccharomyces cerevisiae fungemia in a critically ill patient with acute cholangitis and long term probiotic use

Mustafa Fadhel
, Swapnil Patel
, Edward Liu
, Michael Levitt
, Arif Asif

School of Medicine

Jersey Shore University Medical Center

Research output: Contribution to journal › Article › peer-review

35 Scopus citations

Abstract

Saccharomyces cerevisiae has recently been used as an ingredient in probiotic supplements. Invasive Saccharomyces infection have been documented, and multiple predisposing risk factors have been identified including critical illness, ICU admission, antibiotics use, central venous catheters, probiotics use, and immunosuppression. We report a case of a 74-year-old man admitted for acute cholangitis taking a probiotic supplement containing the subtype Saccharomyces boulardii. He later developed S. cerevisiae fungemia that was successfully treated with Micafungin and Fluconazole.

Original language	English
Pages (from-to)	23-25
Number of pages	3
Journal	Medical Mycology Case Reports
Volume	23
DOIs	https://doi.org/10.1016/j.mmcr.2018.11.003
State	Published - Mar 2019

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Keywords

Fungemia
Micafungin
Probiotic supplement
Saccharomyces boulardii
Saccharomyces cerevisiae

Access to Document

10.1016/j.mmcr.2018.11.003

Cite this

@article{04bf28a5b8984194b0a91a131ddac512,

title = "Saccharomyces cerevisiae fungemia in a critically ill patient with acute cholangitis and long term probiotic use",

abstract = "Saccharomyces cerevisiae has recently been used as an ingredient in probiotic supplements. Invasive Saccharomyces infection have been documented, and multiple predisposing risk factors have been identified including critical illness, ICU admission, antibiotics use, central venous catheters, probiotics use, and immunosuppression. We report a case of a 74-year-old man admitted for acute cholangitis taking a probiotic supplement containing the subtype Saccharomyces boulardii. He later developed S. cerevisiae fungemia that was successfully treated with Micafungin and Fluconazole.",

keywords = "Fungemia, Micafungin, Probiotic supplement, Saccharomyces boulardii, Saccharomyces cerevisiae",

author = "Mustafa Fadhel and Swapnil Patel and Edward Liu and Michael Levitt and Arif Asif",

note = "Publisher Copyright: {\textcopyright} 2018 The Authors",

year = "2019",

month = mar,

doi = "10.1016/j.mmcr.2018.11.003",

language = "English",

volume = "23",

pages = "23--25",

journal = "Medical Mycology Case Reports",

issn = "2211-7539",

publisher = "Elsevier B.V.",

}

TY - JOUR

T1 - Saccharomyces cerevisiae fungemia in a critically ill patient with acute cholangitis and long term probiotic use

AU - Fadhel, Mustafa

AU - Patel, Swapnil

AU - Liu, Edward

AU - Levitt, Michael

AU - Asif, Arif

PY - 2019/3

Y1 - 2019/3

N2 - Saccharomyces cerevisiae has recently been used as an ingredient in probiotic supplements. Invasive Saccharomyces infection have been documented, and multiple predisposing risk factors have been identified including critical illness, ICU admission, antibiotics use, central venous catheters, probiotics use, and immunosuppression. We report a case of a 74-year-old man admitted for acute cholangitis taking a probiotic supplement containing the subtype Saccharomyces boulardii. He later developed S. cerevisiae fungemia that was successfully treated with Micafungin and Fluconazole.

AB - Saccharomyces cerevisiae has recently been used as an ingredient in probiotic supplements. Invasive Saccharomyces infection have been documented, and multiple predisposing risk factors have been identified including critical illness, ICU admission, antibiotics use, central venous catheters, probiotics use, and immunosuppression. We report a case of a 74-year-old man admitted for acute cholangitis taking a probiotic supplement containing the subtype Saccharomyces boulardii. He later developed S. cerevisiae fungemia that was successfully treated with Micafungin and Fluconazole.

KW - Fungemia

KW - Micafungin

KW - Probiotic supplement

KW - Saccharomyces boulardii

KW - Saccharomyces cerevisiae

UR - https://www.scopus.com/pages/publications/85056864642

U2 - 10.1016/j.mmcr.2018.11.003

DO - 10.1016/j.mmcr.2018.11.003

M3 - Article

AN - SCOPUS:85056864642

SN - 2211-7539

VL - 23

SP - 23

EP - 25

JO - Medical Mycology Case Reports

JF - Medical Mycology Case Reports

ER -

Saccharomyces cerevisiae fungemia in a critically ill patient with acute cholangitis and long term probiotic use

Abstract

UN SDGs

Keywords

Access to Document

Other files and links

Fingerprint

Cite this